Literature DB >> 24976529

Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?

Dieter Lemke1,2,3, Markus Weiler1,2,3, Jonas Blaes1,2, Benedikt Wiestler1,2,3, Leonie Jestaedt4, Ann-Catherine Klein1,2, Sarah Löw1,2,3, Günter Eisele5, Bernhard Radlwimmer1,6, David Capper7, Kirsten Schmieder8, Michel Mittelbronn9,10, Stephanie E Combs11, Martin Bendszus4, Michael Weller5, Michael Platten1,3,12, Wolfgang Wick1,2,3.   

Abstract

Human glioblastomas may be hierarchically organized. Within this hierarchy, glioblastoma-initiating cells have been proposed to be more resistant to radiochemotherapy and responsible for recurrence. Here, established stem cell markers and stem cell attributed characteristics such as self-renewal capacity and tumorigenicity have been profiled in primary glioblastoma cultures to predict radiosensitivity. Furthermore, the sensitivity to radiotherapy of different subpopulations within a single primary glioblastoma culture was analyzed by a flow cytometric approach using Nestin, SRY (sex-determining region Y)-box 2 (SOX2) and glial fibrillary acidic protein. The protein expression of Nestin and SOX2 as well as the mRNA levels of Musashi1, L1 cell adhesion molecule, CD133, Nestin, and pleiomorphic adenoma gene-like 2 inversely correlated with radioresistance in regard to the clonogenic potential. Only CD44 protein expression correlated positively with radioresistance. In terms of proliferation, Nestin protein expression and Musashi1, pleiomorphic adenoma gene-like 2, and CD133 mRNA levels are inversely correlated with radioresistance. Higher expression of stem cell markers does not correlate with resistance to radiochemotherapy in the cancer genome atlas glioblastoma collective. SOX2 expressing subpopulations exist within single primary glioblastoma cultures. These subpopulations predominantly form the proliferative pool of the primary cultures and are sensitive to irradiation. Thus, profiling of established stem cell markers revealed a surprising result. Except CD44, the tested stem cell markers showed an inverse correlation between expression and radioresistance. Markers used to define glioma-initiating cells (GIC) are generally not defining a more resistant, but rather a more sensitive group of glioma cells. An exemption is CD44 expression. Also proliferation of the GIC culture itself was not systematically associated with radiosensitivity or - resistance, but a SOX-2 positive, proliferative subgroup within a GIC culture is showing the highest radiosensitivity.
© 2014 International Society for Neurochemistry.

Entities:  

Keywords:  CD133; Glioma-initiating cells; SOX2; profiling; radiotherapy sensitivity; stem cell markers

Mesh:

Substances:

Year:  2014        PMID: 24976529     DOI: 10.1111/jnc.12802

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  16 in total

1.  cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.

Authors:  Anne Berberich; Lara-Marie Schmitt; Stefan Pusch; Thomas Hielscher; Petra Rübmann; Nanina Hucke; Pauline Latzer; Bernd Heßling; Dieter Lemke; Tobias Kessler; Michael Platten; Wolfgang Wick
Journal:  J Neurooncol       Date:  2019-11-28       Impact factor: 4.130

2.  Tweety-Homolog 1 Drives Brain Colonization of Gliomas.

Authors:  Erik Jung; Matthias Osswald; Jonas Blaes; Benedikt Wiestler; Felix Sahm; Torsten Schmenger; Gergely Solecki; Katrin Deumelandt; Felix T Kurz; Ruifan Xie; Sophie Weil; Oliver Heil; Carina Thomé; Miriam Gömmel; Mustafa Syed; Peter Häring; Peter E Huber; Sabine Heiland; Michael Platten; Andreas von Deimling; Wolfgang Wick; Frank Winkler
Journal:  J Neurosci       Date:  2017-06-12       Impact factor: 6.167

3.  Matrix Hyaluronic Acid and Hypoxia Influence a CD133+ Subset of Patient-Derived Glioblastoma Cells.

Authors:  Jee-Wei Emily Chen; Sarah Leary; Victoria Barnhouse; Jann N Sarkaria; Brendan A C Harley
Journal:  Tissue Eng Part A       Date:  2021-12-27       Impact factor: 4.080

4.  Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.

Authors:  Sophie Weil; Matthias Osswald; Gergely Solecki; Julia Grosch; Erik Jung; Dieter Lemke; Miriam Ratliff; Daniel Hänggi; Wolfgang Wick; Frank Winkler
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300

5.  RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells.

Authors:  Harry O King; Tim Brend; Helen L Payne; Alexander Wright; Thomas A Ward; Karan Patel; Teklu Egnuni; Lucy F Stead; Anjana Patel; Heiko Wurdak; Susan C Short
Journal:  Stem Cell Reports       Date:  2017-01-10       Impact factor: 7.765

6.  Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.

Authors:  Eleanna Papa; Michael Weller; Tobias Weiss; Elisa Ventura; Isabel Burghardt; Emese Szabó
Journal:  Cell Death Dis       Date:  2017-12-13       Impact factor: 8.469

7.  MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM.

Authors:  Nina Stojcheva; Gennadi Schechtmann; Steffen Sass; Patrick Roth; Ana-Maria Florea; Anja Stefanski; Kai Stühler; Marietta Wolter; Nikola S Müller; Fabian J Theis; Michael Weller; Guido Reifenberger; Caroline Happold
Journal:  Oncotarget       Date:  2016-03-15

8.  ER stress inducer tunicamycin suppresses the self-renewal of glioma-initiating cell partly through inhibiting Sox2 translation.

Authors:  Yang Xing; Yuqing Ge; Chanjuan Liu; Xiaobiao Zhang; Jianhai Jiang; Yuanyan Wei
Journal:  Oncotarget       Date:  2016-06-14

9.  NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.

Authors:  Sanaz Yahyanejad; Henry King; Venus Sosa Iglesias; Patrick V Granton; Lydie M O Barbeau; Stefan J van Hoof; Arjan J Groot; Roger Habets; Jos Prickaerts; Anthony J Chalmers; Daniëlle B P Eekers; Jan Theys; Susan C Short; Frank Verhaegen; Marc Vooijs
Journal:  Oncotarget       Date:  2016-07-05

10.  Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.

Authors:  Dieter Lemke; Hans-Werner Pledl; Markus Zorn; Manfred Jugold; Ed Green; Jonas Blaes; Sarah Löw; Anne Hertenstein; Martina Ott; Felix Sahm; Ann-Catherine Steffen; Markus Weiler; Frank Winkler; Michael Platten; Zhen Dong; Wolfgang Wick
Journal:  Oncotarget       Date:  2016-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.